ABEA2025: Exclusive Interview with Dr Jun Hu, WuXi XDC

WuXi XDC Shines at Asia-Pacific Biopharma Excellence Awards 2025

ABEA2025 Exclusive Interview with Dr Jun Hu, WuXi XDC
📍 12 March 2025 | Singapore

WuXi XDC, a global leader in the development and manufacturing of Antibody-Drug Conjugates (ADCs), has been recognized as a top innovator at the Asia-Pacific Biopharma Excellence Awards 2025, held in Singapore. This prestigious recognition underscores WuXi XDC’s continued leadership in ADC development and its unwavering commitment to advancing targeted therapies.

At this year’s ceremony, WuXi XDC was honored with multiple accolades, including:
🏆 Best ADC CDMO in Asia
🏆 Best ADC CDMO in China
🏆 Best ADC CRO in Asia
🏆 Best ADC Platform Technology

In an exclusive interview, Dr Jun Hu, Vice President of WuXi XDC, joined Lara Santiago, Portfolio Specialist & Producer at IMAPAC, to share his insights on the company’s journey, key innovations, and the future of ADCs in Asia and beyond.

Stay tuned for this special ABEA 2025 interview as we spotlight one of the region’s most impactful biotech leaders.